New Zealand's Pharmac has announced it will fund Eisai's LENVIMA (lenvatinib) from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer.
Pharmac makes cancer therapy the 26th funded since budget boost
November 11, 2024 BioPharmaLatest News
Latest Video
New Stories
-
A hearing that provided more evidence of the need for meaningful change
October 29, 2026 - - Latest News -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 - - Latest News -
Rebates and net spend are the major PBS story of the past decade
October 28, 2026 - - Latest News -
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News -
Managing an agreement negotiation as a 'prisoner of circumstance'
October 28, 2026 - - Latest News -
Lung scarring killing 11 Australians a day, with one in five cases traced to work
October 28, 2026 - - Latest News -
The stakes are very high on access in a contested budget environment
October 28, 2026 - - Latest News
